Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02219048 · ClinicalTrials.gov registry record · Phase 2
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT02219048 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 51 participants.
The verdict
NCT02219048, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.
Interventions
- DRUG Placebo
- DRUG PF-03715455
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02219048
The ClinicalTrials.gov registry entry for NCT02219048 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02219048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02219048 about?
NCT02219048 is a clinical study titled "An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma". The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.
What is the current status of trial NCT02219048?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2014-11. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02219048?
The interventions under investigation include: Placebo (DRUG), PF-03715455 (DRUG).
Who is sponsoring clinical trial NCT02219048?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.